Class IX Myosins: Motorized RhoGAP Signaling Molecules.


Journal

Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103

Informations de publication

Date de publication:
2020
Historique:
entrez: 27 5 2020
pubmed: 27 5 2020
medline: 13 8 2020
Statut: ppublish

Résumé

Class IX myosins are simultaneously motor and signaling molecules. In addition to myosin class-specific functions of the tail region, they feature unique motor properties. Within their motor region they contain a long insertion with a calmodulin- and a F-actin-binding site. The rate-limiting step in the ATPase cycle is ATP hydrolysis rather than, typical for other myosins, the release of either product. This means that class IX myosins spend a large fraction of their cycle time in the ATP-bound state, which is typically a low F-actin affinity state. Nevertheless, class IX myosins in the ATP-bound state stochastically switch between a low and a high F-actin affinity state. Single motor domains even show characteristics of processive movement towards the plus end of actin filaments. The insertion thereby acts as an actin tether. The motor domain transports as intramolecular cargo a signaling Rho GTPase-activating protein domain located in the tail region. Rho GTPase-activating proteins catalyze the conversion of active GTP-bound Rho to inactive GDP-bound Rho by stimulating GTP hydrolysis. In cells, Rho activity regulates actin cytoskeleton organization and actomyosin II contractility. Thus, class IX myosins regulate cell morphology, cell migration, cell-cell junctions and membrane trafficking. These cellular functions affect embryonic development, adult organ homeostasis and immune responses. Human diseases associated with mutations in the two class IX myosins, Myo9a and Myo9b, have been identified, including hydrocephalus and congenital myasthenic syndrome in connection with Myo9a and autoimmune diseases in connection with Myo9b.

Identifiants

pubmed: 32451867
doi: 10.1007/978-3-030-38062-5_16
doi:

Substances chimiques

Actins 0
GTPase-Activating Proteins 0
MYO9A protein, human 0
myosin IXB 0
rho GTPase-activating protein 0
Myosins EC 3.6.4.1

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

381-389

Auteurs

Peter J Hanley (PJ)

Institute of Molecular Cell Biology, Westfalian Wilhelms University Münster, Münster, Germany.

Veith Vollmer (V)

Institute of Molecular Cell Biology, Westfalian Wilhelms University Münster, Münster, Germany.

Martin Bähler (M)

Institute of Molecular Cell Biology, Westfalian Wilhelms University Münster, Münster, Germany. baehler@uni-muenster.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH